



Dabigatran Versus Warfarin : Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation

Masatsugu Hori, Stuart J. Connolly, Jun Zhu, Li Sheng Liu, Chu-Pak Lau, Prem Pais, Denis Xavier, Sung Soon Kim, Razali Omar, Antonio L. Dans, Ru San Tan, Jyh-Hong Chen, Supachai Tanomsup, Mitsunori Watanabe, Masahide Koyanagi, Michael D. Ezekowitz, Paul A. Reilly, Lars Wallentin and Salim Yusuf the RE-LY Investigators

Stroke. 2013;44:1891-1896; originally published online June 6, 2013; doi: 10.1161/STROKEAHA.113.000990 Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2013 American Heart Association, Inc. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://stroke.ahajournals.org/content/44/7/1891

Data Supplement (unedited) at:

http://stroke.ahajournals.org/content/suppl/2013/06/06/STROKEAHA.113.000990.DC1.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at: http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at: http://stroke.ahajournals.org//subscriptions/

Dabigatran Versus Warfarin

Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation

Masatsugu Hori, MD, PhD; Stuart J. Connolly, MD; Jun Zhu, MD; Li Sheng Liu, MD; Chu-Pak Lau, MD;
Prem Pais, MD; Denis Xavier, MD; Sung Soon Kim, MD; Razali Omar, MD; Antonio L. Dans, MD;
Ru San Tan, MD; Jyh-Hong Chen, MD; Supachai Tanomsup, MD; Mitsunori Watanabe, MD, PhD;
Masahide Koyanagi, BA; Michael D. Ezekowitz, MBChB, DPhil; Paul A. Reilly, PhD;
Lars Wallentin, MD; Salim Yusuf, MD, DPhil; the RE-LY Investigators

Background and Purpose—Intracranial hemorrhage rates are higher in Asians than non-Asians, especially in patients receiving warfarin. This randomized evaluation of long-term anticoagulation therapy subgroup analysis assessed dabigatran etexilate (DE) and warfarin effects on stroke and bleeding rates in patients from Asian and non-Asian countries.
 Methods—There were 2782 patients (15%) from 10 Asian countries and 15 331 patients from 34 non-Asian countries. A Cox regression model, with terms for treatment, region, and their interaction was used.

- *Results*—Rates of stroke or systemic embolism in Asians were 3.06% per year on warfarin, 2.50% per year on DE 110 mg BID (DE 110), and 1.39% per year on DE 150 mg BID (DE 150); in non-Asians, the rates were 1.48%, 1.37%, and 1.06% per year with no significant treatment-by-region interactions. Hemorrhagic stroke on warfarin occurred more often in Asians than non-Asians (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.3–4.7; *P*=0.007), with significant reductions for DE compared with warfarin in both Asian (DE 110 versus warfarin HR, 0.15; 95% CI, 0.03–0.66 and DE 150 versus warfarin HR, 0.22; 95% CI, 0.06–0.77) and non-Asian (DE 110 versus warfarin HR, 0.37; 95% CI, 0.19–0.72 and DE 150 versus warfarin HR, 0.28; 95% CI, 0.13–0.58) patients. Major bleeding rates in Asians were significantly lower on DE (both doses) than warfarin (warfarin 3.82% per year, DE 110 2.22% per year, and DE 150 2.17% per year).
- *Conclusions*—Hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age, and lower international normalized ratio values. Hemorrhagic strokes were significantly reduced by DE in both Asians and non-Asians. DE benefits were consistent across Asian and non-Asian subgroups.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600. (Stroke. 2013;44:1891-1896.)

Key Words: Asia ■ atrial fibrillation ■ bleeding ■ dabigatran ■ intracranial hemorrhage ■ RE-LY ■ warfarin

Patients of Asian ethnicity are at greater risk of hemorrhage while receiving vitamin K antagonist therapy.¹ However, a randomized controlled trial comparing the effects and safety of different anticoagulants has not been reported.

Atrial fibrillation (AF) is responsible for 20% to 30% of ischemic stroke² and anticoagulation reduces this risk, but this benefit is off-set by increased hemorrhage, including hemorrhagic stroke. Warfarin is recommended

for the prevention of stroke in AF in Asian countries but its use is limited by concerns related to the increased risk of hemorrhage. This is reflected in Japanese guidelines for anticoagulation, where the target range of international normalized ratio (INR) control with warfarin in patients aged \geq 70 years is 1.6–2.6.³ New oral anticoagulants have been shown to be effective against stroke with lower rates of hemorrhage; however, there are no reports on the benefits

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.113.000990

Received February 5, 2013; final revision received April 4, 2013; accepted April 8, 2013.

From the Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan (M.H.); Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada (S.J.C., S.Y.); Cardiovascular Institute & Fu Wai Hospital, Beijing, China (J.Z., L.S.L.); Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong (C.-P.L.); St. John's Medical College and Research Institute, Bangalore, India (P.P., D.X.); Yonsei University College of Medicine, Seoul, Korea (S.S.K.); National Heart Institute, Kuala Lumpur, Malaysia (R.O.); Philippine General Hospital, Manila, Philippines (A.L.D.); National Heart Centre, Singapore, Singapore (R.S.T.); National Cheng Kung University Hospital, Tainan, Taiwan (J.-H.C.); Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (S.T.); Clinical Development and Medical Affairs, Nippon Boehringer Ingelheim, Tokyo, Japan (M.W., M.K.); Cardiovascular Research Foundation NY, Thomas Jefferson Medical College, Philadelphia, PA (M.D.E.); Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT (P.A.R.); and Uppsala Clinical Research Center and Department Medical Sciences, Uppsala University, Uppsala, Sweden (L.W.).

The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA. 113.000990/-/DC1.

Correspondence to Masatsugu Hori, MD, PhD, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan. E-mail hori-ma@mc.pref.osaka.jp

^{© 2013} American Heart Association, Inc.

and risk of these agents in Asian patients. The randomized evaluation of long-term anticoagulation therapy (RE-LY) compared the use of dabigatran etexilate (DE), at doses of 110 mg BID and 150 mg BID, with warfarin in patients with AF; and included patients from non-Asian and Asian countries.^{4,5} Overall in RE-LY, DE 110 mg BID was associated with rates of stroke and systemic embolism (SE) that were similar to those associated with warfarin, as well as lower rate of major bleeding. DE 150 mg BID, as compared with warfarin, was associated with lower rates of stroke and SE but similar rates of major hemorrhage.

In this analysis, we report the effects of DE versus warfarin among Asians and non-Asians on ischemic and hemorrhagic strokes and on bleeding.

Methods

Trial Design and Participants

RE-LY was an international multicenter study, in which 18113 patients were recruited from 951 centers in 44 countries.^{4,5} Two fixed doses (110 or 150 mg BID) of DE administered in a blinded manner were compared with open-label warfarin (target INR of 2.0–3.0) in patients with AF. Patients were not included if they had a severe heartvalve disorder, recent stroke, increased risk of hemorrhage, a creatinine clearance <30 mL/min, liver disease, or pregnancy. The Asian countries included were China, Hong Kong, Japan, South Korea, Taiwan, India, Malaysia, Philippines, Singapore, and Thailand. All remaining countries were considered to be non-Asian.

Outcomes

The primary outcome was the occurrence of stroke or SE. Strokes were classified as ischemic and hemorrhagic. Major bleeding was defined as a reduction in the hemoglobin level of ≥ 20 g/L, transfusion of ≥ 2 U of blood, or symptomatic bleeding in a critical area or organ. Life-threatening bleeding was a subcategory of major bleeding that consisted of fatal bleeding, symptomatic intracranial hemorrhage, bleeding with a decrease in the hemoglobin level of ≥ 50 g/L, or bleeding requiring transfusion of ≥ 4 U of blood or inotropic agents or necessitating surgery. All other bleeding was considered as minor bleeding, which was reported by investigators. All major bleeds were adjudicated blindly by ≥ 2 adjudicators. Net clinical benefit was defined as a composite of stroke, SE, pulmonary embolism, myocardial infarction, death, or major bleeding.

Statistical Analyses

The study outcomes were compared between the randomized treatment groups within 2 regions, Asia and non-Asia, separately for DE 110 mg BID versus warfarin, and DE 150 mg BID versus warfarin. A Cox regression model was used to calculate hazard ratios (HRs), confidence intervals (CIs), and *P* values. The model contained terms for treatment, region, and the interaction. Event rates stratified by treatment and region were calculated. As this was a post hoc subgroup analysis, all *P* values should be viewed cautiously. As differences were observed in age between regions, an age-adjusted Cox regression analysis was also performed. The model additionally included the effects of age and the interaction with treatment. All analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, NC).

Results

Demographic Characteristics of the Study Patients

There were 2782 patients from the 10 Asian countries (15%), and 15331 patients from the remaining non-Asian countries.

The baseline demographic characteristics of the 3 randomized treatment groups were well balanced within Asian and non-Asian subgroups, but there were some differences in the characteristics between Asian and non-Asian patients (Table 1). Asians were on average 4 years younger than non-Asians and had substantially lower body weight (66 versus 86 kg), with a higher rate of previous stroke (24% versus 10%) but less previous myocardial infarction (9% versus 18%). The values of estimated creatinine clearance were lower in Asians than in non-Asians (65.3 \pm 22.1 versus 74.2 \pm 28.1 mL/min).

Ethnicity of the subjects corresponded with the analysis by region. There were a total of 2875 Asians in the RE-LY trial and 2782 patients in this Asian regional analysis. The stroke or SE and bleeding rates by ethnic origin were similar to the geographic analysis (data not shown).

INR Control for Warfarin Treatment

Time in therapeutic range was lower in Asian patients (mean, 54.5%) than in non-Asian (66.2%), with less time above (10.1% in Asian versus 14.0% in non-Asian) and more time below the therapeutic range (35.4% versus 19.8%; Table 2).

Stroke and Other Efficacy Outcomes

The rates of stroke or SE in Asian patients were 3.06% per year on warfarin, 2.50% per year on DE 110 mg BID, and 1.39% per year on DE 150 mg BID (Figure 1; Table 3). In Asian patients, compared with warfarin, the rate was nonsignificantly lower with DE 110 mg BID (HR, 0.81; 95% CI, 0.54-1.21) and the rate was significantly lower with DE 150 mg BID (HR, 0.45; 95% CI, 0.28–0.72). In non-Asians, the rates of stroke or SE were 1.48% per year on warfarin, 1.37% per year on DE 110 mg BID, and 1.06% per year on DE 150 mg BID (Table 3). For DE 110 mg BID versus warfarin, the rates of stroke or SE were nonsignificantly lower (HR, 0.93; 95% CI, 0.74-1.17); for DE 150 mg BID versus warfarin, the rates were significantly lower (HR, 0.72; 95% CI, 0.56-0.92). However, there was no treatment-by-region interaction for either dose of DE showing consistency of the treatments effects across regions for the RE-LY study primary outcome.

There were no treatment-by-region interactions for either dose of DE on stroke, ischemic stroke, hemorrhagic stroke, myocardial infarction, and death from any cause. However, the absolute rates of stroke were numerically higher in Asians than in non-Asians in all treatment groups (2.39 versus 1.27 for DE 110 mg BID, 1.34 versus 0.96 for DE 150 mg BID, 2.78 versus 1.37 for warfarin; Table 3). Furthermore, rates of ischemic stroke in warfarin groups were doubled in Asians (Asians 2.02% per year versus non-Asians 0.98% per year).

Bleeding

The rates of major bleeding in Asian patients were 3.82% per year on warfarin, 2.22% per year on DE 110 mg BID, and 2.17% per year on DE 150 mg BID (Figure 2; Table 4). The corresponding rates in non-Asian patients were 3.53%, 2.99%, and 3.52% per year. In Asian patients, compared with warfarin, the rate was significantly lower with both DE 110 mg BID (HR, 0.57; 95% CI, 0.38–0.85) and DE 150 mg BID

		ian 1782)	Non-Asian (n=15 331)		
Age, y					
Mean, SD	68.0	9.8	72.1	8.3	
<65 (n, %)	746	26.8	2235	14.6	
65–74 (n, %)	1273	45.8	6621	43.2	
≥75 (n, %)	763	27.4	6475	42.2	
Weight, kg					
Mean, SD	66.3	12.8	85.6	19.2	
Blood pressure, mm Hg					
Systolic (mean, SD)	129.0	17.5	131.3	17.4	
Diastolic (mean, SD)	77.6	10.7	76.9	10.5	
Sex					
Men (n, %)	1775	63.8	9739	63.5	
Type of atrial fibrillation					
Paroxysmal (n, %)	770	27.7	5173	33.7	
Persistent (n, %)	1151	41.4	4638	30.3	
Permanent (n, %)	861	30.9	5514	36.0	
Creatinine clearance, mL/min					
Mean, SD	65.3	22.1	74.2	28.1	
<50 (n,%)	740	26.6	2814	18.4	
50–79 (n, %)	1427	51.3	7126	46.5	
≥80 (n, %)	606	21.8	5238	34.2	
CHADS, score					
Mean, SD	2.2	1.1	2.1	1.1	
0–1 (n, %)	841	30.2	4942	32.2	
2 (n, %)	917	33.0	5536	36.1	
3–6 (n, %)	1024	36.8	4852	31.6	
Previous stroke					
Yes (n, %)	672	24.2	1601	10.4	
Previous myocardial infarction					
Yes (n, %)	260	9.3	2745	17.9	
Heat failure					
Yes (n, %)	1011	36.3	4782	31.2	
Diabetes mellitus					
Yes (n, %)	698	25.1	3523	23.0	
Hypertension					
Yes (n, %)	1980	71.2	12303	80.2	
Medication in use at the baseline					
Aspirin (n, %)	1309	47.1	5844	38.1	
ARB (n, %)	914	32.9	3422	22.3	
ACE-I (n, %)	790	28.4	7333	47.8	
β-Blocker (n, %)	1286	46.2	10112	66.0	
Amiodarone (n, %)	394	14.2	1582	10.3	
Verapamil (n, %)	130	4.7	941	6.1	
Proton pump inhibitor (n, %)	222	8.0	2345	15.3	
H, blocker (n, %)	155	5.6	603	3.9	
Long-term VKA therapy					
Experience (n, %)	1015	36.5	7969	52.0	

 Table 1.
 Baseline Demographic Characteristics of Asian and

 Non-Asian Patients
 Patients

(HR, 0.57; 95% CI, 0.38–0.84). There was a statistically significant interaction (P=0.008) between treatment and region when comparing DE 150 mg BID versus warfarin in Asians with that in non-Asians. As there is a previously reported interaction between age and the effect of dabigatran on major bleeding compared with warfarin,⁶ we performed an analysis with adjustment for age. In this analysis, this interaction was somewhat attenuated (P=0.06).

The rate of hemorrhagic stroke in warfarin-treated patients was 0.75% per year in Asian patients, whereas 0.32% per year in non-Asian patients (HR, 2.4; 95% CI, 1.3-4.7; P=0.007), despite the younger age, the greater time below therapeutic range and the comparable baseline systolic and diastolic blood pressure in Asians (Table 3). In DE-treated patients, the rates of hemorrhagic stroke in both subgroups were much lower than for warfarin, ranging from 0.09 to 0.17% (Table 3). Regarding gastrointestinal major bleeding, there was a significant interaction (P=0.009) between treatment and region when comparing DE 150 mg BID versus warfarin (Table 4). This interaction was still present after adjustment for age (P=0.04). Compared with warfarin, both DE 110 mg BID and DE 150 mg BID significantly reduced total bleeding in Asians (DE 110 mg BID versus warfarin HR, 0.48; 95% CI, 0.40-0.56/DE 150 mg BID versus warfarin HR, 0.60; 95% CI, 0.51-0.70). For both DE doses compared with warfarin, there was a highly significant treatment-by-region interaction for total bleeding (P<0.0001 with or without age adjustment).

For warfarin, the rates of all bleeding outcomes (major, gastrointestinal major, life-threatening major, minor, total, intracranial, and hemorrhagic stroke) were numerically higher in Asians than non-Asians, despite comparable blood pressure, younger age, and lower INR values, whereas those on DE tended to be lower in Asians than non-Asians (Tables 3 and 4).

The rates of stroke and SE and major bleeding, and the number of patients in each country in RE-LY are given in an Appendix in the online-only Data Supplement.

Net Clinical Benefit

Net clinical benefit was consistently in favor of DE for both doses compared with warfarin, in both Asians and non-Asians (Table 4). However, only the DE 150 mg BID versus warfarin in Asians was clearly superior (HR, 0.66; 95% CI, 0.52–0.83). The treatment-by-region interaction was significant (P=0.004) for this comparison.

Adverse Events

In both Asians and non-Asians, the most common adverse event on DE was dyspepsia-like symptoms (DE 110 mg BID: Asian 16.1%, non-Asian 12.1%; DE 150 mg BID: Asian 15.9%, non-Asian 11.5%; warfarin: Asian 8.7%, non-Asian; 5.4%).

Table 2. Time Ratios of INR for Warfarin Treatment Groups

		Asian (n=	=880)	Non-Asian (n=4909)					
INR	<2	2–3	>3	<2	2–3	>3			
Mean, %	35.4	54.5	10.1	19.8	66.2	14.0			
Median, %	30.8	56.5	8.1	15.4	68.9	11.6			

ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and VKA, vitamin K antagonist.

INR indicates international normalized ratio.




Figure 1. Cumulative hazard rates for the primary outcome of stroke or systemic embolism, according to treatment group in Asian population. DE indicates dabigatran etexilate.

Discussion

The key findings of this analysis of RE-LY are that the effects of dabigatran against stroke and SE are similar in Asian and non-Asian patients for both doses of dabigatran compared with warfarin. The second key finding is that although Asian patients on warfarin had considerably more time below therapeutic range and were younger, there was a trend for more bleeding in Asian than in non-Asian patients. For total bleeding and for hemorrhagic stroke, the rates in Asian patients on warfarin were significantly higher than in non-Asians. Finally, for total bleeding there was a statistically significant interaction between treatment and region (Asian versus non-Asian) indicating that dabigatran reduced the risk of bleeding outcomes more in Asians than in non-Asians.

The rates of all bleeding outcomes (major, gastrointestinal major, life-threatening major, minor, total, intracranial, and

Dahigatran 110 mg BID

hemorrhagic stroke) on warfarin were numerically higher in Asians than non-Asians (Tables 3 and 4). This may be because of the genetic differences in blood coagulation between Asians and non-Asians. Indeed, differences in warfarin sensitivity genotyping were reported between Asians and non-Asian,⁷ and no factor V-Leiden mutations were found in Asians.8 However, these genetic differences may minimally contribute to the ethnic difference in bleeding on warfarin because adjustment of warfarin dose with INR values was commonly performed both in Asians and in non-Asians in this controlled trial. In the present study, bleeding outcomes on warfarin showed a higher rate in Asians compared with non-Asians, despite younger age, warfarin control with more time below therapeutic range, and comparable blood pressures in Asians. This strongly suggests Asian propensity to bleed on warfarin. In particular, a 2.4-fold higher risk of hemorrhagic stroke is consistent with previous reports. A previous report on patients with AF treated with warfarin demonstrated a 4-fold higher HR for intracranial hemorrhage in Asians compared with whites.¹ Furthermore in the recent report of meta-analysis on the incidence of intracerebral hemorrhage, the incidence was \approx 2-fold higher in Asians compared with whites.⁹ The underlying cause of this higher rate may be associated with Asian sensitivity to warfarin which might be explained by ethnic differences in terms of hemostatic state or vascular properties. Cerebral microbleeds were reported to be more frequent in warfarin users with intracerebral hemorrhage compared with nonantithrombotic users (odds ratio, 2.7), and in pooled follow-up data for warfarin users, presence of microbleeds at baseline was associated with an increased risk of subsequent intracerebral hemorrhage (odds ratio, 3.0).¹⁰ The other report showed higher prevalence of microbleeds in Asian patients with intracerebral hemorrhage compared with those of non-Asians (68.4% versus 56.2%).¹¹ These reports may suggest

Warfarin

		Dabiyatrai	тто під ы	D			Dabigatia	Wariann				
	Asian (n=923)						sian =933)		-Asian 5143)	_	Asian (n=926)	Non-Asian (n=5096)
	Event Number (%/y)	HR (95% Cl)	Event Number (%/y)	HR (95% Cl)	Interaction <i>P</i> Value	Event Number (%/y)	HR (95% CI)	Event Number (%/y)	HR (95% CI)	Interaction <i>P</i> Value		Number %/y)
Stroke or systemic embolism	44 (2.50)	0.81 (0.54–1.21)	139 (1.37)	0.93 (0.74–1.17)	0.56	25 (1.39)	0.45 (0.28–0.72)	109 (1.06)	0.72 (0.56–0.92)	0.09	53 (3.06)	149 (1.48)
Stroke	42 (2.39)	0.85 (0.56–1.29)	129 (1.27)	0.93 (0.73–1.18)	0.73	24 (1.34)	0.48 (0.29–0.78)	98 (0.96)	0.70 (0.54–0.90)	0.18	48 (2.78)	138 (1.37)
lschemic stroke	36 (2.05)	1.01 (0.63–1.61)	116 (1.14)	1.17 (0.89–1.53)	0.60	20 (1.12)	0.55 (0.32–0.95)	83 (0.81)	0.82 (0.61–1.10)	0.20	35 (2.02)	99 (0.98)
Hemorrhagic stroke	2 (0.11)	0.15 (0.03–0.66)	12 (0.12)	0.37 (0.19–0.72)	0.27	3 (0.17)	0.22 (0.06–0.77)	9 (0.09)	0.28 (0.13–0.58)	0.76	13 (0.75)	32 (0.32)
MI*	9 (0.51)	0.88 (0.36–2.17)	89 (0.88)	1.36 (0.99–1.87)	0.38	9 (0.50)	0.87 (0.35–2.13)	88 (0.86)	1.33 (0.97–1.83)	0.38	10 (0.58)	65 (0.65)
Death from any cause	88 (5.01)	0.98 (0.73–1.32)	358 (3.53)	0.89 (0.77–1.02)	0.59	72 (4.01)	0.78 (0.57–1.07)	366 (3.57)	0.90 (0.78–1.04)	0.42	88 (5.09)	399 (3.96)

Dabigatran 150 mg BID

Table 3. Efficacy Outcomes With Dabigatran Versus Warfarin Among Asians and Non-Asians

P values for treatment-by-region interaction are calculated using Cox regression model with the terms for treatment, region and treatment-by-region interaction. Cl indicates confidence interval; HR, hazard ratio; and MI, myocardial infarction.

*MI includes silent MI.




Figure 2. Cumulative hazard rates for major bleeding, according to treatment group in Asian population. DE indicates dabigatran etexilate.

ethnic difference of prevalence of microbleeds and susceptibility to intracranial hemorrhage. Ethnic difference in salt sensitivity to intracranial hemorrhage may also be involved.¹²

The rates of stroke or SE or ischemic stroke in patients on warfarin were \approx 2-fold higher in Asians compared with non-Asians. The lower time in therapeutic range in warfarin control in Asians and higher proportion of patients with previous stroke in Asians (Asian 24% versus non-Asian 10%) may contribute to the higher rates of stroke or SE in Asians. A similar finding was also observed in the previous subgroup analysis of the RE-LY trial in which rates of stroke are \approx 2-fold higher in patients with previous stroke or transient ischemic attack than those without in all treatment groups.¹³ The consistency of the treatment effect of dabigatran against stroke (in comparison to warfarin) observed in this analysis is not surprising. In many different subgroup analyses of RE-LY, there has been no evidence of any subgroup responding differently to dabigatran.⁵ The present analysis comparing Asians to non-Asians is in line with the previous findings.

In contrast, we have previously reported that there is an interaction between age and the bleeding effects of both doses of dabigatran compared with warfarin, which indicates that the benefits of dabigatran compared with warfarin seen in younger patients are attenuated significantly in older patients.⁶ This age interaction would seem to at least in part explain the results of the present study related to a greater reduction in bleeding with dabigatran compared with warfarin in Asians. In general, Asians were younger than non-Asians in RE-LY and they would, therefore, be expected to have a greater benefit from dabigatran over warfarin. Indeed the highly significant interaction related to dabigatran effect on major bleeding in the unadjusted analysis is somewhat attenuated (P=0.06) when the analysis is adjusted for age. For total bleeding, however, the interaction is highly significant for both dabigatran doses in both adjusted and unadjusted for age (P < 0.0001). The large differential in major bleeding also contributes to the significant net clinical benefit of DE 150 mg BID in Asians and the strong treatment-by-region interaction. Poorer INR control on warfarin could also explain a greater benefit from dabigatran in Asian patients as the time in range in Asians was lower than in non-Asians. Undercontrol of INR below therapeutic range may cause greater risk of ischemic stroke, but Nieuwlaat et al¹⁴ have reported that time below range can also predict a greater risk of bleeding possibly reflecting greater variability in INR control.

The present study has some limitations. The number of Asians (2782) is relatively small compared with that of non-Asians (15 331), and the presented results are an exploratory subgroup analysis; all the P values are, therefore, nominal.

Table 4. Risk of Bleeding With Dabigatran Versus Warfarin Among Asians and Non-Asians

		Dabiga	tran 110 m	g BID			Dabiga		Warfarin			
		sian =923)		-Asian 5092)			sian :933)		-Asian 5143)	_	Asian (n=926)	Non-Asian (n=5096)
	Event Number (%/y)	HR (95% CI)	Event Number (%/y)	HR (95% CI)	Interaction <i>P</i> Value	Event Number (%/y)	HR (95% CI)	Event Number (%/y)	HR (95% CI)	Interaction <i>P</i> Value		Number 6/y)
Major bleeding	39 (2.22)	0.57 (0.39–0.85)	303 (2.99)	0.85 (0.73–0.99)	0.07	39 (2.17)	0.57 (0.38–0.84)	360 (3.52)	1.00 (0.87–1.16)	0.008	66 (3.82)	355 (3.53)
Gastrointestinal major bleeding	20 (1.15)	0.82 (0.45–1.49)	114 (1.14)	1.13 (0.86–1.47)	0.34	17 (0.96)	0.69 (0.37–1.27)	170 (1.69)	1.67 (1.31- 2.14)	0.009	24 (1.41)	101 (1.01)
Life-threatening major bleeding	16 (0.91)	0.41 (0.23–0.73)	131 (1.29)	0.72 (0.58–0.90)	0.07	23 (1.28)	0.58 (0.34–0.97)	156 (1.52)	0.85 (0.69 -1.06)	0.17	38 (2.20)	180 (1.79)
Minor bleeding	178 (10.12)	0.47 (0.39–0.56)	1388 (13.69)	0.86 (0.80–0.92)	<0.0001	223 (12.43)	0.60 (0.51–0.71)	1564 (15.27)	0.98 (0.92–1.05)	<0.0001	340 (19.66)	1591 (15.81)
Total bleeding	206 (11.72)	0.48 (0.40–0.56)	1549 (15.27)	0.85 (0.79–0.91)	<0.0001	251 (13.99)	0.60 (0.51–0.70)	1743 (17.02)	0.98 (0.91–1.04)	<0.0001	381 (22.03)	1785 (17.74)
Intracranial hemorrhage	4 (0.23)	0.20 (0.07–0.60)	23 (0.23)	0.32 (0.20–0.51)	0.46	8 (0.45)	0.40 (0.18–0.92)	30 (0.29)	0.41 (0.27- 0.63)	0.95	19 (1.10)	71 (0.71)
Net clinical benefit	147 (8.36)	0.85 (0.68–1.06)	726 (7.16)	0.94 (0.85–1.04)	0.39	116 (6.47)	0.66 (0.52–0.83)	739 (7.22)	0.95 (0.86–1.05)	0.004	167 (9.65)	766 (7.61)

P values for treatment-by-region interaction are calculated by using Cox regression model with the terms for treatment, region and treatment-by-region interaction. Major and intracranial hemorrhages are adjudicated. The net clinical benefit outcome is the composite of stroke, systemic embolism, pulmonary embolism, myocardial infarction including silent myocardial infarction, death, or major bleeding. Cl indicates confidence interval; and HR, hazard ratio. Moreover, patient demographics in Asians and non-Asians were not comparable; INR control is poorer and age is younger in Asians than in non-Asians. There was also a higher frequency of previous stroke, a lower frequency of myocardial infarction, and less frequent previous exposure to vitamin K antagonist therapy in Asians, similar to what was seen in the subanalysis of Japanese patients in RE-LY.¹⁵ Patients' ethnicity and lifestyle, including dietary differences, are heterogeneous in both Asians and non-Asians. It should also be noted that minor bleeding, a component of total bleeding, is not adjudicated. However, rates of bleeding outcomes on warfarin, including hemorrhagic stroke, were higher in Asians than in non-Asians, and the rates are compatible with previous epidemiological studies.¹⁹ In contrast, the efficacy and safety in DE arms were comparable between Asians and non-Asians.

In summary, the present study shows consistency of efficacy profiles of DE in both Asians and non-Asians. The safety profile of DE was also confirmed in Asians and overall. The rates of all bleeding outcomes, including hemorrhagic stroke on warfarin, were higher in Asians than in non-Asians.

Sources of Funding

This study was funded by Boehringer Ingelheim.

Disclosures

Dr. M. Hori has received consultancy fees from Boehringer Ingelheim, Bayer, Bristol Myers-Squibb and Pfizer. Dr. M. Watanabe and Mr. M. Koyanagi are employees of Nippon Boehringer Ingelheim. Dr. P.A. Reilly is an employee of Boehringer Ingelheim. The other authors have no conflicts to report.

References

- Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309–315.
- Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. *Stroke*. 2005;36: 1115–1119.

- JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. *Circ J.* 2010;74:2479–2500.
- Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran. *Am Heart J.* 2009;157:805–810, 810.e2.
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009;361:1139–1151.
- 6. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation*. 2011;123:2363–2372.
- Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. *Mayo Clin Proc.* 2009;84:1079–1094.
- Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. *Am J Med. Genet.* 1997;73:334–336.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol.* 2010;9:167–176.
- Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T, et al.; Edinburgh Stroke Study Group. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. *Stroke*. 2010;41:1222–1228.
- Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. *Neurology*. 2006;66:165–171.
- Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ*. 2009;339:b4567.
- Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al.; RE-LY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. *Lancet Neurol.* 2010;9:1157–1163.
- Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, et al.; ACTIVE Investigators. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. *Thromb Res.* 2012;129:715–719.
- Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation–sub-analysis in Japanese population in RE-LY trial. *Circ J*. 2011;75:800–805.


	Country	DE 110mg	hid	Warfar	in	HR (95% CI)
	(N)	#evts	% per year	#evts	% per year	
rgentina	530					
Stroke/SEE Major Bleeds		9	2.80	7	2.28	1.24 (0.46, 3.34) 1.62 (0.59, 4.45)
istřalia Stroke/SEE	209	2	1 56	2	1 46	
Major Bleeds	100	2 5	1.56	2 4	1.46 2.92	1.08 (0.15, 7.66) 1.34 (0.36, 5.01)
stria Stroke/SEE	129	0		0		n/a 1.00 (0.06, 16.00)
Major Bleeds lgium	440	1	1.31	1	1.25	1.00 (0.06, 16.00)
Stroke/SEE	110	67	1.89	3	0.97 2.92	1.98 (0.49, 7.90)
Major Bleeds azil	249		2.21			Andreas, Joseph Andreas, Marca State
Stroke/SEE Major Bleeds		0		28	1.52	n/a n/a
lgaria Stroke/SEE	363		0 0 0			
Major Bleeds		23	0.82 1.24	2 1	0.86 0.43	0.94 (0.13, 6.70) 2.95 (0.31, 28.32)
nada Stroke/SEE	1150	7	0.91	7	0.91	0.99 (0.35, 2.82)
Major Bleeds ina, Peoples	541	36	4.69	24	3.13	1.51 (0.90, 2.54)
public of	241					
Stroke/SEE Major Bleeds		7	1.94	10	2.87	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
lombia Stroke/SEE	13	0		0		n/a
laior Bleeds		o		0		n/a
ch Republic Stroke/SEE	350	3	1.23	4	1.71	0.71 (0.16, 3.16)
Major Bleeds Mmark	247	3 5	1.23 2.05	42	1.71 0.86	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Stroke/SEE	271	25	1.00	2 10	1.03 5.13	0.97 (0.14, 6.88)
Major Bleeds nland	265	5	2.49	10		
Stroke/SEE Major Bleeds		4	2.23	36	1.70 3.41	1.34 (0.30, 5.99) 0.32 (0.07, 1.60)
anče	177					
Stroke/SEE Major Bleeds		2	1.69	3 2	2.52	0.71 (0.12, 4.22)
rmány Stroke/SEE	659	7	1 71	0		
Major Bleeds		12	1.71 2.92	1 3 1 3	1.94 3.15	$\begin{array}{c} 0.88 \\ 0.32, 2.42 \\ 0.93 \\ (0.42, 2.04 \end{array}$
						0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
						HR (95% CI) of DE 110mg bid vs Warfarin * Value/s out of range

* Value/s out of range

	Country	DE	hid	Warfar	rin	HR (95% CI)	
	(N)	110mg #evts	% per year	#evts	% per year		
eec <mark>e</mark> Stroke/SEE	249	4	2.54	2	1.30	1.95 (0.36, 10.67)	
Major Bleeds	90	3	1.90	23	1.95	1.01 (0.20, 5.00)	
Major Bleeds ng Kong Stroke/SEE Major Bleeds	90	2	3.17	1	1.58	$\begin{array}{c} 1.89 \\ 2.08 \end{array} \begin{pmatrix} 0.17, \ 20.86 \\ 0.19, \ 22.91 \end{pmatrix}$	•
igary Stroke/SEE	172	0					
Major Bleeds lia	578	3	2.67	1 4	0.90 3.59	n/a 0.76 (0.17, 3.40)	
Stroke/SEE	570	6 4	1.81	11	3.37 1.84	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Major Bleeds	689						
troke/SEE Lajor Bleeds		10 18	2.33 4.20	9 16	$2.12 \\ 3.76$	1.09 (0.44, 2.69) 1.13 (0.58, 2.21)	
lý Stroke/SEE	237	0		25	1.34	n/a 0.41 (0.08, 2.13)	
ajor Bleeds an	326	2	1.40	5	3.34	0.41 (0.08, 2.13)	
troke/SEE ajor Bleeds		2	1.385.53	4	2.653.31	0.52 (0.10, 2.84) 1.68 (0.55, 5.15)	
aysia troke/SEE	185	5	4.09	1000			
ajor Bleeds	84	ĭ	0.82	56	$\begin{array}{r}4.24\\5.09\end{array}$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
troke/SEE	07	0		02	2.00	n/a	
ajor Bleeds herlands	1266				3.86	n/a	
troke/SEE ajor Bleeds		14 13	1.62	12	1.41 2.23	1.16 (0.54, 2.51) 0.67 (0.33, 1.35)	
wáy troke/SEE	115	3	3.38	3	3.28	1.01 (0.20, 5.02)	F
ajor Bleeds u	80	0		4	4.37	n/a	
troke/SEE ajor Bleeds		1	2.38	0	2.67	n/a 0.87 (0.05, 13.99)	
lippines troke/SEE	157	5		6			
ajor Bleeds	485	4	5.15 4.12	10	6.15 10.24	0.86 (0.26, 2.81) 0.40 (0.13, 1.28)	
and troke/SEE ajor Bleeds		4 3	1.27 0.95	1 8	0.32 2.56	4.05 (0.45, 36.22) 0.37 (0.10, 1.39)	•

HR (95% CI) of DE 110mg bid vs Warfarin * Value/s out of range

	Country	DE	233	Warfa	rin	HR (95% CI)	
	(N)	110mg #evts	% per year	#evts	% per year		
rtugal Stroke/SEE	117	0		2	3.47	n/a	
Major Bleeds		ŏ		õ		n/a	
mania Stroke/SEE	44	0		1	5.01	n/a	
Major Bleeds ssia	300	0		0		n/a	
Stroke/SEE	500	4 2	2.12	2	1.08	1.99 (0.36, 10.85) 0.99 (0.14, 7.02)	3 1 •
lajor Bleeds Igapore	59	2	1.06	2	1.08	0.99 (0. <mark>1</mark> 4, 7. <mark>0</mark> 2)	
troke/SEE	55	0 1		24	5.42 10.85	n/a 0.20 (0.02, 1.82)	
lajor Bleeds Vakia	156	1	2.50	4	10.85	0.20 (0.02, 1.82)	
troke/SEE	130	3	2.60	2 4	1.78	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
ajor Bleeds	174	5	4.34	4	3.55	1.24 (0.33, 4.63)	
th Africa troke/SEE	174	1	0.91	4	4.09	0.21 (0.02, 1.91)	
troke/SEE ajor Bleeds	226	1	0.91	45	4.09	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
th Korea troke/SEE	336	6	2.57	5	2.13	1.23 (0.37, 4.02)	· · · · · · · · · · · · · · · · · · ·
lajor Bleeds	10100	7	3.00	6	2.56	1.17 (0.39, 3.48)	
iń troke/SEE	107	0		0		n/a	
ajor Bleeds	08004.755	ĭ	1.62	ŏ		n/a	
dén troke/SEE	277	1	0.52	3	1 51	0.34 (0.04, 3.30)	
lajor Bleeds		1 4	2.09	4	1.51 2.02	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
tžerland troke/SEE	29	0		0			
lajor Bleeds		0 1	5.35	0	6.14	n/a 0.88 (0.05, 14. <mark>0</mark> 4)) • •
wan	355						
ltroke/SEE Iajor Bleeds		4	1.48	5 19	1.94 7.38	0.75 (0.20, 2.80) 0.34 (0.14, 0.80)	
iland	155					Carlo and a static convertion of the second	
Stroke/SEE Major Bleeds		7	7.27 3.11	4 4	4.14	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
rkéy	21						
troke/SEE Major Bleeds		1	7.39	0	6.47	n/a n/a	
caine	228		3825 ANO A			and a second	
Stroke/SEE Major Bleeds		1	0.782.33	0	1.53	n/a 1.60 (0.27, 9.58)	
alor precub		3	2.33	4	1.35	1.00 (0.27, 5.58)	
							0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.
							HR (95% CI) of DE 110mg bid vs Warfarin * Value/s out of range




	Country	DE 150mg	hid	Warfar	in	HR (95% CI)
	(N)	150mg #evts	% per year	#evts	<pre>% per year</pre>	
gentina Stroko (SPR	530	2	0.00	7	0.00	
troke/SEE lajor Bleeds		1 2 1 2	0.92	6	2.28	0.41 (0.11, 1.58) 1.94 (0.73, 5.18)
třalia troke/SEE	209	3 7	2.22 5.19	2 4	1.46	1.50 (0.25, 8.97)
ajor Bleeds tria	129	7	5.19	4	1.46 2.92	1.50 {0.25, 8.97} 1.80 {0.53, 6.14}
troke/SEE	125	2 1	2.48	0		n/a 0.92 (0.06, 14.77)
ajor Bleeds gium	440	1	1.24	1	1.25	0.92 (0.06, 14.77)
troke/SEE ajor Bleeds		0 9	2.88	39	0.97 2.92	n/a 0.99 (0.39, 2.48)
zil	249					
troke/SEE ajor Bleeds		23	1.50	28	1.52	$1.02 (0.14, 7.22) \\ 0.36 (0.10, 1.37) $
garia troke/SEE	363					
ajor Bleeds		32	1.31 0.88	2	0.86	1.51 (0.25, 9.06) 2.07 (0.19, 22.81)
ada troke/SEE	1150	8	1.04	7	0.91	1.14 (0.41.3.13)
ator Bleeds	541	29	1.04 3.76	24	0.91 3.13	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
na, Peoples ublic of troke/SEE	241					
troke/SEE ajor Bleeds		4	1.10	10	2.87 1.43	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
ombia troke/SEE	13	0				
ajor Bleeds		0		0		n/a n/a
ch Republic troke/SEE	350	1	0 4 2	4	1 71	
ajor Bleeds	0.4.7	1 7	0.42	42	1.71 0.86	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
märk troke/SEE	247	10	1.02	2 10	1.03	0.99 (0.14, 7.05)
ajor Bleeds land	265	10	5.09	10	5.13	0.99 {0.14, 7.05 1.02 {0.42, 2.45}
troke/SEE	205	32	1.67	36	1.703.41	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
ajor Bleeds nce	177	2	1.12	6	3.41	
troke/SEE ajor Bleeds		1	0.88	3	2.52	0.35 (0.04, 3.38) 0.53 (0.05, 5.87)
many	659					
troke/SEE ajor Bleeds		10	0.47 2.36	13	1.94 3.15	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
						0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.
						HR (95% CI)_of DE 150mg bid vs Warfarin

HR (95% CI) OF DE 150mg bid vs Warfarin * Value/s out of range

	Country	DE	bid	Warfai	rin	HR (95% CI)	
	(N)	150mg #evts	% per year	#evts	% per year		
reece, (and	249						
Stroke/SEE Major Bleeds		03	1.79	23	1.30	n/a 0.96 (0.19, 4.74)	
Stroke/SEE	90	3	4 91	1	1.58	2 85 (0 30 27 39)	
Major Bleeds	1 7 0	32	4.91 3.27	1	1.58 1.58	2.85 (0.30, 27.39) 2.08 (0.19, 22.92)	
ngary Stroke/SEE	172	0		1	0.90	n/a	
Major Bleeds dia	578	03	2.72	1 4	0.90	n/a 0.73 (0.16, 3.27)	
Stroke/SEE	576	25	0.58	11 6	3.37	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Major Bleeds cael	689	5	1.44	6	1.84	0.81 (0.25, 2.67)	
Stroke/SEE		20	0.70	9 16	2.12 3.76	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Major Bleeds aly Stroke/SEE	237		4.64				
Stroke/SEE Major Bleeds		04	2.61	25	1.34 3.34	n/a 0.78 (0.21, 2.92)	
an Stroke/SEE	326						
ajor Bleeds		1 5	0.67	4 5	2.653.31	0.25 (0.03, 2.27)	
aysia	185					Contract Text (Address to Section 1) Review (Texture) (Texture	
Stroke/SEE Major Bleeds		3	$2.32 \\ 4.64$	56	4.24	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
ićo troke/SEE	84	0		0		Service Service Control (Control (Control))	
lajor Bleeds		ŏ		02	3.86	n/a n/a	
hérlands Stroke/SEE	1266	14	1.61	12	1.41	1.16 (0.53, 2.50)	
ajor Bleeds	115	15	1.73	19	2.23	0.76 (0.39, 1.50)	
way Stroke/SEE	115	1 2	1.17	3	3.28	0.35 (0.04, 3.33)	
lajor Bleeds	80	2	2.35	4	4.37	0.57 (0.10, 3.10)	
Stroke/SEE	00	0		0		n/a	
Major Bleeds Llippines	157	0		1	2.67	n/a	
Stroke/SEE	157	1	1.01	6	6.15	0,16 (0.02, 1.37)	
Major Bleeds .and	485			10	10.24	n/a	
Stroke/SEE Major Bleeds		4	1.29	1 8	0.32	4.05 (0.45, 36.25) 0.88 (0.32, 2.42)	_
ajor breeus		1	2.20	0	2.50	0.00 (0.32, 2.12)	
						0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5	្ទ
							40
						HR (95% CI) of DE 150mg bid vs Warfarin * Value/s out of range	

	Country	DE	b i d	Warfa	rin	HR (95% CI)
	(N)	150mg #evts	% per year	#evts	% per year	
rtugal Stroke/SEE	117	0		2	3.47	n/a
Major Bleeds mania Stroke/SEE	4 4	0 1 2	4.79 9.58	0	5.01	n/a 1,06 (0.07, 17.05)
Major Bleeds ssia Stroke/SEE	300		9.58		1.08	n/a 0.48 (0.04.5.34)
lajor Bleeds Igapore Stroke/SEE	5 9	1 2	1.04	22	1.08	0.48 (0.04, 5.34) 0.97 (0.14, 6.90)
lajor Bleeds ovakia	156	02	4.83	2 4	5.42 10.85	n/a 0.40 (0.07, 2.21)
troke/SEE Lajor Bleeds th Africa	174	1	0.87 0.87	2 4	1.78 3.55	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
ltroke/SEE Lajor Bleeds Lth Korea	336	0	2.66	4 5	4.09 5.11	n/a 0.53 (0.13, 2.22)
troke/SEE Jajor Bleeds in	107	4 5	1.71 2.14	5 6	2.13 2.56	0.80 (0.22, 2.99) 0.82 (0.25, 2.68)
troke/SEE lajor Bleeds	The second second	1	$\begin{smallmatrix}1&.4&6\\1&.4&6\end{smallmatrix}$	0 0		n/a n/a
dén troke/SEE ajor Bleeds	277	4 3	1.93	3 4	1.51 2.02	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
tžerland troke/SEE ajor Bleeds	29	0		0	6.14	n/a n/a
wan troke/SEE ajor Bleeds	355	7	2.63	5	1.94	1.36 (0.43, 4.28)
iland troke/SEE	155	0 5		4	4.14	n/a
ajor Bleeds key troke/SEE	21	0	4.93	4		1.18 (0.32, 4.43)
ajor Bleeds aine troke/SEE	228	0 2	1.51	1	6. <mark>4</mark> 7	n/a n/a
Major Bleeds		ĩ	0.76	ž	1.53	0.51 (0.05, 5.65)
						0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
						HR (95% CI) of DE 150mg bid vs Warfarin * Value/s out of range



List of Asian Investigators

China: X.J. Bai, W. Gao, X. Gao, D.M. Guan, Z.S. He, Q. Hua, H. Li, L. Li, W.M. Li, G.P. Lu, S. Lv, K. Meng, H.Y. Niu, D.G. Qi, S.Y. Qi, F. Qian, N.L. Sun, H.Y. Wang, N.F. Wang, Y.M. Yang, H. Zeng, F. Zhang, F.R. Zhang, L. Zhang; Hong Kong (China): G.C.P. Chan, W.K. Chan, W.S. Chan, C.L. Lau, H.F. Tse, P.T. Tsui, C.M. Yu, C.S. Yue; India: D.K. Agarwal, R.K. Aggarwal, Arulvenkatesh R., A. Bharani, J.S. Bhuvaneswaran, R.B. Byrapaneni, P. Chandwani, S. Chopra, N. Desai, V. Deshpande, N.P. Golla, J.B. Gupta, K.K. Haridas, J. Hiremath, A.S. Jain, M. Jain, D.A. Jhala, J. Joseph, M. Kaila, A. Kannaiyan, S. Kumar, P. Kuruvila, V.K. Mahorkar, A. Metha, A.M. Naik, S. Narayanan, P.S. Pais, R.B. Panwar, C. Reddy, J.P.S. Sawhney, S.M. Shah, S. Sharma, G.S. Shetty, N. Sinha, N.N. Sontakke, A. Srinivas, M.R. Trivedi, P.S. Vadagenalli, M. Vijayakumar; Japan: T. Aoyagi, H. Eguma, K. Fujii, M. Fukuchi, M. Fukunami, Y. Furukawa, J. Furuya, S. Goto, K. Haneda, S. Hara, M. Hiroe, Y. lesaka, T. lijima, Y. Ishibashi, K. Iwade, T. Kajiya, S. Kakinoki, S. Kamakura, H. Kasanuki, Y. Katayama, Y. Kihara, K. Kimura, S. Kobayashi, K. Kono, Y. Koretsune, N. Marui, I. Maruyama, T. Matsuyama, H. Meno, N. Miyamoto, S. Morikawa, K. Myojin, T. Nakamura, Y. Nishi, S. Ogawa, T. Ogawa, H. Onaka, T. Sakakibara, S. Sakurai, Y. Sasaki, H. Sato, M. Sugii, K. Sumii, S. Suzuki, M. Takagi, T. Takenaka, K. Takeuchi, S. Tanaka, J. Tanouchi, S. Uchiyama, K. Ueda, Y. Ueyama, T. Ujihira, M. Usui, M. Yagi, T. Yamada, T. Yamaguchi, H. Yamamoto, M. Yasaka, M. Yokochi, E. Zen; Malaysia: A.K. Abd Ghaphar, C.K. Ang, K.H. Chee, A.F.Y. Fong, O. Ismail, S. Jeyaindran, S. Kaur, T.C. Lee, O. Razali, R.S. Sandhu, R.P. Shah, S. Suganthi, S. Zainal Abidin; *Philippines*: M.T.B. Abola, J.C. Anonuevo, R.S. Arellano, C. Dioquino, D.R. Maranon, D.D. Morales, E.B. Reyes, G.G. Rogelio, A.A. Roxas Jr., D.J.V. Sulit; Singapore: P.L. Chia, D. Foo, K.L. Sim; South Korea: T.J. Cha, J.G. Cho, I.S. Choi, J.I. Choi, K.J. Choi, K.R. Han, J.H. Heo, S.W. Jang, T.S. Kang, H.S. Kim, K.S. Kim, S.J. Kim, Y.H. Kim, Y.N. Kim, M.H. Lee, M.Y. Lee, G.B. Nam, D.J. Oh, H.W. Park, J.S. Park, T.H. Rho, D.G. Shin, E.K. Shin; Taiwan: Y.J. Chang, C.H. Chen, M.Y.C. Chen, J.J. Cheng, T.R. Chiang, W.T. Chung, C.H. Hsia, C.Y. Hsu, H.H. Hu, J.S. Jeng, W.T. Lai, L.M. Lien, K.H. Lin, C.H. Liu, H.S. Lo, G.S. Peng, H.L. Po, S.J. Ryu, C.D. Tsai, L.M. Tsai, C.D. Tseng, J.H. Wang, S.F. Wang, S.P. Yang; Thailand: Kiatchoosakun S., R. Krittayaphong, S. Kuanprasert, T. Ngarmukos, T. Simtharakaew, B. Sukanandachai, A. Sukonthasam, A. Suwanagool, and Tatsanavivat P.